



Please type a plus sign (+) inside this box → **+**

PTO:SB.21 (06-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/006,430	
	Filing Date	December 10, 2001	
	First Named Inventor	Mark J. Graham	
	Group Art Unit	1635	
	Examiner Name	Sean McGarry	
Total Number of Pages in This Submission	6	Attorney Docket Number	ISIS0072-100 (RTS-0341)

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below)		
<table border="1"><tr><td>Remarks</td><td>Express Mail no.: EV 147609962 US Date Deposit: May 9, 2003</td></tr></table>			Remarks	Express Mail no.: EV 147609962 US Date Deposit: May 9, 2003
Remarks	Express Mail no.: EV 147609962 US Date Deposit: May 9, 2003			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gwilym J. O. Attwell/45,449
Signature	
Date	May 9, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No.: ISIS0072-100 (RTS-0341)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Graham *et al.*

Serial No.: 10 006,430

Group Art Unit: 1635

Filed: December 10, 2001

Examiner: S. McGarry

Title: ANTISENSE MODULATION OF CD81 EXPRESSION

Express Mail Number: EV 147609962 US

Deposited: May 9, 2003

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE

This paper is filed in response to the Office Action dated April 9, 2003.

REMARKS

Claims 1-10, 12-15, and 21-32 are subject to a restriction requirement. The Office Action required Applicants to "elect an antisense compound targeted to one (1) target region from claim 1 and an antisense oligonucleotide sequence from claim 3 that corresponds to the elected region of claim 1. During a teleconference with the Examiner on May 5, 2003, the Examiner affirmed that the Office Action imposed a Restriction Requirement instead of an Election of Species Requirement.

A requirement to restrict an application to one of several inventions may be made if two or more independent *and* distinct inventions are claimed in the invention (*see* 35 U.S.C. § 121). The MPEP, however, indicates that restriction is proper if the claimed inventions are "either independent *or* distinct." (*see* MPEP § 803, internal citations omitted; emphasis added). "Independent" is defined as inventions which "are not connected in design, operation, or effect . . ." (MPEP § 802.01). The term "distinct"

